Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of HRS-4029 for the Treatment of Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial

NCT07739160 is registered in ClinicalTrials.gov with Beijing Suncadia Pharmaceuticals Co., Ltd as lead sponsor.

NCT NCT07739160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07739160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of HRS-4029 for the Treatment of Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial
Lead sponsor
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
July 31, 2027
Enrollment
340 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke